NYSE:GWAY - Greenway Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Greenway Health logoGreenway Health LLC is a United States-based company, which provides clinical, financial and administrative solutions for healthcare providers. The Company provides integrated clinically driven revenue cycle management and electronic health record (EHR) solutions. Its suite of solutions and services is PrimeSUITE, which integrates clinical, financial and administrative data in a single database to enable views of patient records and workflow throughout each patient encounter, reduce clinical and administrative errors, and allow for the exchange of data between its customers and the healthcare community. It offers its solutions by offering managed business services, such as clinically-driven revenue cycle and EHR-enabled research services.

Receive GWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for GWAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryHealth Care Technology
SectorN/A
SymbolNYSE:GWAY
CUSIP39679B10
Phone+1-302-6365400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Greenway Health (NYSE:GWAY) Frequently Asked Questions

What is Greenway Health's stock symbol?

Greenway Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "GWAY."

What is the consensus analysts' recommendation for Greenway Health?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Greenway Health in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Greenway Health been receiving favorable news coverage?

News stories about GWAY stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Greenway Health earned a daily sentiment score of 0.21 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 46.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Greenway Health?

Shares of GWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Greenway Health?

Greenway Health's mailing address is 1340 N Park St, CARROLLTON, GA 30117-2262, United States. The healthcare company can be reached via phone at +1-302-6365400.


MarketBeat Community Rating for Greenway Health (NYSE GWAY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Greenway Health and other stocks. Vote "Outperform" if you believe GWAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.